Bill Ackman: 2014 Trading World Champion
Published January 8, 2015
Bill Ackman's Pershing Square Capital Management returned approximately 40.4% net of fees in 2014, generating $4.5 billion in net gains for investors and producing one of the strongest full-year performances of any large hedge fund in the world. In a year where the hedge fund industry averaged roughly 3% and many high-profile managers struggled to keep pace with a modestly rising S&P 500, Ackman's concentrated activist strategy delivered returns that placed him in a category of his own. Managing approximately $14 billion in assets, Pershing Square proved that the activist model — taking large, concentrated positions in a handful of companies and pushing for change — could produce outsized gains at institutional scale. LCH Investments subsequently named Ackman one of the world's top 20 hedge fund managers, with lifetime net gains reaching $11.6 billion through 2014.
The defining trade of Ackman's year — and arguably the single most profitable position taken by any hedge fund manager in 2014 — was the Allergan campaign. Beginning in February, Pershing Square quietly accumulated a 9.7% stake in the pharmaceutical company, building a position worth approximately $4 billion through a series of transactions over several weeks. In April, the strategy revealed itself: Valeant Pharmaceuticals launched an unsolicited $51 billion takeover bid for Allergan, with Pershing Square publicly backing the deal and offering its shares to the combined entity. The market immediately understood that Allergan was in play, and the stock surged on the announcement.
What followed was a seven-month corporate battle that became one of the most closely watched M&A situations of the year. Allergan's board rejected the Valeant bid, adopted a poison pill, and sued Pershing Square and Valeant in federal court alleging insider trading violations related to the pre-announcement share accumulation. Ackman fought back aggressively, waging a proxy campaign to replace Allergan's board and force a shareholder vote on the deal. The legal and strategic complexity of the campaign was extraordinary — a simultaneous battle across corporate boardrooms, courtrooms, and the court of public opinion. Ackman's willingness to pursue the trade through escalating opposition reflected the conviction-driven approach that has defined his career.
The situation resolved in November when Actavis entered the picture as a white-knight acquirer, offering $66 billion for Allergan — substantially more than Valeant's original bid. Allergan's board accepted the Actavis offer, and Pershing Square exited its entire position at a profit of approximately $2.6 billion. The trade lasted less than nine months from initial accumulation to final exit. In absolute dollar terms, it was one of the largest single-position gains recorded by any hedge fund in 2014 and demonstrated the power of the activist-bidder collaboration model that Ackman had helped pioneer.
Beyond Allergan, Pershing Square's concentrated portfolio contributed to the year's strong result. Ackman typically holds only six to ten core positions, each representing a meaningful percentage of the fund's capital, and applies activist pressure to unlock value through board representation, strategic proposals, and public campaigns. This approach had produced transformative results in prior years at companies like Canadian Pacific Railway, where Ackman's push for a management change revitalized the company, and General Growth Properties, where Pershing Square helped restructure the firm out of bankruptcy. The 2014 portfolio was built on the same model of deep research, concentrated conviction, and active engagement with management.
The broader market environment of 2014 made Ackman's result particularly striking. The S&P 500 gained 11.4%, a respectable but unspectacular figure that masked considerable dispersion underneath. Oil prices collapsed from above $100 to below $60, Russia's annexation of Crimea injected geopolitical uncertainty, and the Federal Reserve completed its QE3 taper while the European Central Bank moved to negative interest rates for the first time. The US dollar surged, emerging markets stumbled, and fixed-income markets behaved in ways that confounded the consensus. In this environment, the median hedge fund returned approximately 3%, and numerous marquee names posted flat or negative years. Ackman's 40.4% was not just good relative to the market — it was exceptional relative to the professional competition.
Ackman's 2014 stands as one of the most complete single-year performances in the modern history of activist investing. The Allergan trade alone would have been sufficient to define the year, but the overall portfolio return confirmed that the result was not a one-position anomaly. It is worth noting that Ackman's subsequent years would prove far more difficult — the Valeant position that grew out of the Allergan partnership would eventually produce enormous losses, and the Herbalife short that ran concurrently through 2014 remained a costly open position. But judged on the merits of the calendar year alone, 2014 was the high-water mark of Ackman's career to that point: $4.5 billion in net gains, a 40.4% net return at $14 billion in assets, and a single trade that netted $2.6 billion. That is why Bill Ackman is the 2014 Trading World Champion.
« Full 2014 Top 5 Rankings | 2013 Champion | 2015 Champion »
Based on publicly available information as of Jan 2015. About our process.